(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 January 2012 (05.01.2012)

PCT

(10) International Publication Number
WO 2012/003405 A4

(51) International Patent Classification:
C07D 401/04 (2006.01) *C07D 413/14* (2006.01)
C07D 401/14 (2006.01) *C07D 417/14* (2006.01)
C07D 405/14 (2006.01) *A61K 31/4155* (2006.01)

(21) International Application Number:
PCT/US201 1/042716

(22) International Filing Date:
30 June 201 1 (30.06.201 1)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/360,236 30 June 2010 (30.06.2010) US
61/406,845 26 October 2010 (26.10.2010) US
61/474,563 12 April 201 1 (12.04.201 1) US

(71) Applicant *(for all designated States except US):* **IRONWOOD PHARMACEUTICALS, INC.** [US/US]; 301 Binney Street, 2nd Floor, Cambridge, MA 02142 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only):* **KIM, Charles** [US/US]; 348 Franklin St. Apt. 4D, Cambridge, MA 021398 (US). **NAKAI, Takashi** [JP/US]; 7 Gardner Street, Newton, MA 02458 (US). **WAI-HO LEE, Thomas** [US/US]; 665 Lowell Street, Unit 60, Lexington, MA 02420 (US). **MOORE, Joel** [US/US]; 4 Cherry Street, Lexington, MA 02421 (US). **PERL, Nicholas, Robert** [US/US]; 1569 Beacon Street, Apt. 44, Brookline, MA 02446 (US). **ROHDE, Jason** [US/US]; 311 Lowell Street, #1124, Andover, MA 01810 (US). **IYENGAR, Rajesh, R.** [IN/US]; 23 Stratford Road, West Newton, MA 02465 (US). **MERMERIAN, Ara** [US/US]; 18 Island Hill Avenue, Unit 212, Melrose, MA 02176 (US).

(74) Agents: **WONG, King, L.** et al; Kenyon & Kenyon LLP, One Broadway, New York, NY 10004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available):* AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: SGC STIMULATORS

(57) Abstract: Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.



Formula I

WO 2012/003405 A4

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

Date of publication of the amended claims: 23 Febmary 2012

heterocyclic ring and each said 5-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R^7; or

each R^7 is independently selected from halogen, -CN, -NO_2, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-8} cycloalkyl ring, -OR^8, -SR^8, -$N(R^8)_2$, or an oxo group; wherein each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

each R^8 is independently selected from hydrogen, a C_{1-4} alkyl, C_{1-4} haloalkyl or a C_{3-8} cycloalkyl ring; wherein each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

alternatively, two instances of R^8 linked to the same nitrogen atom of R^7, together with said nitrogen atom of R^7, form a 5 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 5 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S;

R^A is selected from hydrogen, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl,

with the proviso that when ring B is unsubstituted phenyl and ring D is unsubtituted pyrimidinyl (X is N and o is zero), R^C is not methyl or ethyl, and

with the proviso that the compound of Formula I is not 2,6-bis(1-benzyl-5-butylpyrazol-3-yl)pyridine.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ring B is phenyl.

3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 3 and wherein each J^B is independently selected from halogen, a C_{1-6} aliphatic or -OR^B.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein each J^B is independently selected from halogen atoms.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein each J^B is independently selected from fluoro or chloro.

6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein each J^B is fluoro.